Prepare Your Regulatory Strategy for FDA’s New Real-World Evidence Guidance

The U.S. Food and Drug Administration (FDA) recently announced a significant policy shift that reshapes how real-world evidence (RWE) fits into regulatory strategy.

For certain types of medical device submissions, the FDA will now accept RWE without requiring identifiable, individual patient-level data. While the update applies to specific medical device submissions today, the agency also signaled its intent to explore similar changes for drugs and biologics.

For RWE directors and health economics and outcomes research (HEOR) leaders, this announcement opens new strategic possibilities, particularly for organizations that have struggled with data access limitations when building regulatory submissions using large-scale databases.

Why this matters now

Historically, FDA expectations around RWE hinged on patient-level data, often tied to identifiable information or explicit consent. That requirement limited how secondary data sources like claims databases, EHR networks, and registries could be used.

For RWE directors and HEOR leaders working on evidence strategies, this requirement created practical challenges. Even when de-identified datasets contained millions of longitudinal patient records across diverse populations, sponsors faced constraints on what could be analyzed and submitted at the patient level.

Since 2016, only 35 drug, biologic, or vaccine applications have leveraged RWE, compared with more than 250 medical device premarket authorizations.¹ While some of that difference reflects distinct regulatory frameworks, the FDA has noted that RWE use in submissions has plateaued, signaling deeper structural challenges.

What changed in the FDA’s real-world evidence guidance

FDA Commissioner Marty Makary put it plainly: “We’re removing unnecessary barriers that have prevented us from using powerful real-world evidence to get life-changing treatments to patients faster.”

For medical device submissions, the implications are immediate. De-identified data from hospital systems, insurance claims networks, and integrated EHR platforms can now support certain types of device submissions without acquiring prior patient-level data requirements.

These data sources reflect real-world treatment patterns, population diversity, and longitudinal outcomes at a scale that clinical trials cannot replicate.

For drug and biologic sponsors, the announcement is directional. The FDA stated that it “intends to consider updating its guidance” for drugs and biologics, indicating this approach may expand beyond devices. While it is not yet policy, the announcement provides a clear signal of how real-world evidence guidance is evolving.

What this means for your strategy

For medical device companies, the question is straightforward: how quickly can you adapt your evidence generation strategy to leverage this new pathway?

For pharmaceutical and biologic sponsors, the urgency is different but equally important. While updates for drugs and biologics remains under consideration, this announcement clarifies how the FDA is thinking about real-world evidence guidance. Organizations that begin preparing now will be positioned to move faster when guidance expands.

Three priorities should guide strategic thinking:

Data provenance will matter more than ever

Without patient-level detail, the FDA will scrutinize data quality, traceability, and validation. The agency stated it will evaluate submissions “on an application-by-application basis.” Secondary aggregated data or datasets of unclear origin may fall short. Primary source data with documented collection methodologies and clear audit trails will be essential.

Longitudinal linkage is your competitive edge

Regulatory questions require continuity across time and care settings. Treatment patterns, safety signals, and comparative effectiveness depend on reconstructed patient journeys. The FDA’s updated posture makes this possible without re-identification, but only if your data sources and infrastructure deliver true longitudinal continuity. Tokenized linkage across payers, providers, pharmacies, and labs is the foundation of defensible RWE.

Analytical expertise turns data into evidence

Data access alone is not enough. Regulatory-ready RWE requires specialized RWE and outcomes research expertise. The gap between “we have data” and “we have regulatory-ready evidence” is filled by methodological rigor, clinical understanding, and experience navigating what regulators need to see.

Best practices for building regulatory-ready RWE

For RWE and HEOR leaders preparing submissions, these practices reflect both FDA expectations and operational reality.

Engage the FDA early and often

Align on RWE use before analysis begins. Share your rationale, feasibility assessments, and study design early, then refine based on feedback. Waiting until submission increases the risk of exclusion.

Justify your data source selection

Conduct feasibility assessments across candidate sources, document why alternatives were excluded, and provide clear rationale for your final selection. Your justification should address whether the source adequately captures the exposure, outcomes, and confounders your design requires.

Validate key variables

Claims algorithms and EHR-derived endpoints require validation in the intended context of use. Novel variables should be validated before primary analysis and built into timelines upfront.

Pre-specify and document as you go

Pre-specified protocols and statistical analysis plans demonstrate transparency. Document confounder selection, missing data approaches, and sensitivity analyses as you go. Building audit trails early avoids costly reconstruction later.

Plan for data transformation

Mapping source data to standardized formats takes time and often reveals data quality issues. Account for this in your timeline and ensure your data partner can support transformation requirements.

What comes next

The FDA has signaled an evolution in real-world evidence guidance. Organizations that align data quality, longitudinal linkage, and analytical expertise now will be better positioned as RWE pathways expand.

Ready to explore what the new real-world evidence guidance means for your regulatory strategy?

Speak with one of our experts to learn how our primary source, longitudinally linked data can accelerate your evidence generation plans.

---

1. “FDA Eliminates Major Barrier to Using Real-World Evidence in Drug and Device Application Reviews,” FDA, December 15, 2025, https://www.fda.gov/news-events/press-announcements/fda-eliminates-major-barrier-using-real-world-evidence-drug-and-device-application-reviews

Inovalon and design® and Inovalon® are trademarks of Inovalon, Inc.